PAK4 Antibody
| Code | Size | Price |
|---|
| PSI-3077-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-3077-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
PAK4 Antibody: KIAA1142, p21-activated kinase 4, PAK-4
Application Note:
PAK4 antibody can be used for the detection of PAK4 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
PAK4 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6. These proteins are not activated by Cdc42/Rac binding. PAK4 was initially identified as a novel effector of Cdc42Hs. Co-expression of PAK4 and Cdc42Hs resulted in induction of filopodia and actin polymerization, showing that it is involved in cytoskeletal reorganization. Other experiments have shown PAK4 to be essential for embryonic viability and proper neuronal development. PAK4 has also been implicated in anchorage-independent growth of tumor cells and is required for activation of several cancer prosurvival pathways.
Background References:
- Jaffer ZM and Chernoff J. p21-activated kinases: three more join the Pak. Int. J. Biochem. Cell Biol. 2002; 34:713-7.
- Abo A, Qu J, Cammarano MS, et al. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J. 1998; 17:6527-40.
- Cotteret S, Jaffer ZM, Beeser A, et al. p21-activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylated BAD. Mol. Cell. Biol. 2003; 23:5526-39.
Buffer:
PAK4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
PAK4 antibody was raised against a 13 amino acid synthetic peptide from near the center of human PAK4.
The immunogen is located within amino acids 210 - 260 of PAK4.
The immunogen is located within amino acids 210 - 260 of PAK4.
NCBI Gene ID #:
10298
NCBI Official Name:
p21 protein (Cdc42/Rac)-activated kinase 4
NCBI Official Symbol:
PAK4
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 65 kDa
Observed: 70 kDa
Observed: 70 kDa
Protein Accession #:
NP_005875
Protein GI Number:
5031975
Purification:
PAK4 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction,Neuroscience,Cancer
SPECIFICITY:
PAK4 antibody is predicted to not cross-react with other PAK family proteins.
Swissprot #:
O96013
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | PAK4 Peptide | PSI-3077P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|